PDGFRB and germ cell tumor: In this context pazopanib, a multitarget TKI against VEGFR 1–3, platelat derived growth factor (PDGFR) and c-KIT was used in a single-arm phase 2 study for patients with refractory germ cell tumors after at least failure of ≥2 platinum-based regimens.